5 completed, 2 not yet recruiting, 2 terminated, 1 active not recruiting. 11 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 5, Not yet recruiting 2, Terminated 2, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Pulmonary Sarcoidosis: new trials by email Literature Review of Pulmonary Sarcoidosis trials Research Report on Pulmonary Sarcoidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016) Tulisokibart, Placebo, Background prednisone therapy - Pulmonary Sarcoidosis | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 158 | 2026-11-06 | 2026-10-09 |
| An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations XTMAB-16, Placebo - Pulmonary Sarcoidosis | Phase 2 | Not yet recruiting | Xentria, Inc. | 182 | 2026-10-30 | 2026-10-21 |
| Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis OATD-01, Placebo - Pulmonary Sarcoidosis | Phase 2 | Recruiting | Molecure S.A. | 96 | 2024-03-21 | 2026-10-08 |
| An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis XTMAB-16 - Pulmonary Sarcoidosis | Phase 2 | Completed | Xentria, Inc. | 31 | 2024-03-01 | 2026-10-16 |
| Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations XTMAB-16 or Placebo - Pulmonary Sarcoidosis | Phase 1 / Phase 2 | Active not recruiting | Xentria, Inc. | 32 | 2023-11-10 | 2026-10-02 |
| Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis CMK389, Placebo - Pulmonary Sarcoidosis | Phase 2 | Completed | Novartis Pharmaceuticals | 62 | 2020-09-23 | 2025-04-13 |
| Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis Efzofitimod 1.0 mg/kg or Placebo, Efzofitimod 3.0 mg/kg or Placebo, Efzofitimod 5.0 mg/kg or Placebo - Pulmonary Sarcoidosis | Phase 1 / Phase 2 | Completed | aTyr Pharma, Inc. | 37 | 2019-01-29 | 2023-07-18 |
| Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis ACZ885, Placebo - Pulmonary Sarcoidosis | Phase 2 | Completed | Novartis Pharmaceuticals | 40 | 2016-12-19 | 2021-10-04 |
| Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis Methionine, DOTANOC - Pulmonary Sarcoidosis | Phase 2 / Phase 3 | Terminated | Turku University Hospital | 5 | 2016-05-01 | 2026-10-07 |
| A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis PD 0360324, Normal Saline for injection - Pulmonary Sarcoidosis | Phase 2 | Terminated | Pfizer | 1 | 2013-03-15 | 2020-01-06 |
| Treatment of Pulmonary Sarcoidosis With Pentoxifylline Pentoxifylline - Pulmonary Sarcoidosis | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 100 | 1999-02-01 | 2008-03-04 |
Sarcoidosis, Pulmonary (11) · Sarcoidosis (3) · Granuloma (2) · Inflammation (2) · Autoimmune Diseases (1) · Lung Diseases (1) · Lung Diseases, Interstitial (1) · Lymphoproliferative Disorders (1)
Hemic and Lymphatic Diseases (11) · Hypersensitivity (11) · Hypersensitivity, Delayed (11) · Immune System Diseases (11) · Lymphatic Diseases (11) · Respiratory Tract Diseases (11) · Lung Diseases (10) · Lung Diseases, Interstitial (10) · Lymphoproliferative Disorders (10) · Sarcoidosis (8) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Immunoproliferative Disorders (1)
68Ga-DOTANOC (1) · Injections (1) · Methionine (1) · OATD-01 (1) · Pentoxifylline (1) · Saline Solution (1) · canakinumab (1)
Xentria, Inc. (3) · Novartis Pharmaceuticals (2) · Merck Sharp & Dohme LLC (1) · Molecure S.A. (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Pfizer (1) · Turku University Hospital (1) · aTyr Pharma, Inc. (1)
United States (8) · United Kingdom (4) · Czechia (3) · Denmark (3) · Germany (3) · Poland (3) · Netherlands (2) · Finland (1) · France (1) · Greece (1) · Norway (1) · Spain (1)
Dariusz Stencel, MD (1) · Gennyne Walker (1) · Juhani Knuuti, MD, PhD (1)
2023 (1), 2025 (1)